MEDIMI AB AK (79T) - Net Assets
Based on the latest financial reports, MEDIMI AB AK (79T) has net assets worth €1.26K EUR (≈ $1.47K USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.79 Million ≈ $2.10 Million USD) and total liabilities (€1.79 Million ≈ $2.09 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See MEDIMI AB AK balance sheet quality to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.26K |
| % of Total Assets | 0.07% |
| Annual Growth Rate | -61.56% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 38.9 |
MEDIMI AB AK - Net Assets Trend (2021–2025)
This chart illustrates how MEDIMI AB AK's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 79T company net worth.
Annual Net Assets for MEDIMI AB AK (2021–2025)
The table below shows the annual net assets of MEDIMI AB AK from 2021 to 2025. Also explore net asset growth rate of MEDIMI AB AK to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €332.69K ≈ $388.95K |
-92.18% |
| 2024-12-31 | €4.25 Million ≈ $4.97 Million |
-69.08% |
| 2023-12-31 | €13.75 Million ≈ $16.08 Million |
-9.85% |
| 2022-12-31 | €15.25 Million ≈ $17.83 Million |
+0.07% |
| 2021-12-31 | €15.24 Million ≈ $17.82 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to MEDIMI AB AK's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3558804600.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €332.69K | 100.00% |
| Total Equity | €332.69K | 100.00% |
MEDIMI AB AK Competitors by Market Cap
The table below lists competitors of MEDIMI AB AK ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Knights Group Holdings plc
LSE:KGH
|
$1.70 Million |
|
Kaixin Auto Holdings
NASDAQ:KXIN
|
$1.71 Million |
|
AfriTin Mining Ltd
LSE:ATM
|
$1.71 Million |
|
Gossan Resources Ltd
V:GSS
|
$1.71 Million |
|
Superior Mining International Corp
V:SUI
|
$1.70 Million |
|
NSJ GOLD CORP.
F:9PZ
|
$1.70 Million |
|
Vastra Hamnens Restaurangdrift Ab
ST:VH
|
$1.70 Million |
|
Altiplano Metals Inc
V:APN
|
$1.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MEDIMI AB AK's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,252,000 to 332,694, a change of -3,919,306 (-92.2%).
- Net loss of 3,192,250 reduced equity.
- Share repurchases of 5,000 reduced equity.
- Other factors decreased equity by 722,056.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-3.19 Million | -959.52% |
| Share Repurchases | €5.00K | -1.5% |
| Other Changes | €-722.06K | -217.03% |
| Total Change | €- | -92.18% |
Book Value vs Market Value Analysis
This analysis compares MEDIMI AB AK's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.36x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.00x to 4.36x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.04 | €0.00 | x |
| 2022-12-31 | €0.03 | €0.00 | x |
| 2023-12-31 | €0.01 | €0.00 | x |
| 2024-12-31 | €0.00 | €0.00 | x |
| 2025-12-31 | €0.00 | €0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MEDIMI AB AK utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -959.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6627.74%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 5.12x
- Recent ROE (-959.52%) is below the historical average (-324.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -107.34% | -1529.45% | 0.06x | 1.16x | €-17.89 Million |
| 2022 | -101.01% | -745.73% | 0.11x | 1.19x | €-16.93 Million |
| 2023 | -103.63% | -392.89% | 0.18x | 1.50x | €-15.63 Million |
| 2024 | -348.75% | -308.49% | 0.44x | 2.58x | €-15.25 Million |
| 2025 | -959.52% | -6627.74% | 0.03x | 5.12x | €-3.23 Million |
Industry Comparison
This section compares MEDIMI AB AK's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $6,410,097,571
- Average return on equity (ROE) among peers: 16.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MEDIMI AB AK (79T) | €1.26K | -107.34% | 1420.95x | $1.70 Million |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $692.18 Million | 21.94% | 0.78x | $2.39 Billion |
| RENAU.UNSP.ARD 1/5 EO-20 (56S0) | $2.51 Billion | 34.85% | 1.01x | $17.02 Billion |
| TEVANO SYSTEMS HLDGS INC. (7RBA) | $-736.70K | 0.00% | 0.00x | $210.67K |
| STEVANATO GROUP SPA O.N. (87N) | $841.66 Million | 15.96% | 0.69x | $1.05 Billion |
| Carl Zeiss Meditec AG (AFX) | $2.17 Billion | 13.36% | 0.40x | $2.23 Billion |
| CARL ZEISS MEDITEC ADR 1 (AFXA) | $2.17 Billion | 13.36% | 0.40x | $2.14 Billion |
| Bio-gate AG (BIG1) | $3.77 Million | -14.43% | 0.38x | $7.12 Million |
| COLOPLAST SP.ADR 1/10 DK1 (CBH) | $8.29 Billion | 56.75% | 3.52x | $12.73 Billion |
| ESSILORLUXOTTICA 1/2/O.N. (ESLC) | $41.00 Billion | 5.75% | 0.57x | $67.43 Billion |
About MEDIMI AB AK
Servana AB engages in the digital development business. The company was formerly known as Medimi AB. Servana AB is based in Lund, Sweden. Servana AB operates as a subsidiary of PixelFox Group AB.